Acular Ls is owned by Allergan.
Acular Ls contains Ketorolac Tromethamine.
Acular Ls has a total of 12 drug patents out of which 0 drug patents have expired.
Acular Ls was authorised for market use on 30 May, 2003.
Acular Ls is available in solution/drops;ophthalmic dosage forms.
Acular Ls can be used as a method of treating ocular pain and/or enhancing ocular comfort, a method of treating ocular pain, a method of treating or preventing ocular pain in a patient, a method of treating or preventing ocular pain and burning, a method of treating or reducing ocular pain and burning/stinging, a method of treating or preventing ocular pain and burning/stinging following corneal surgery, a method of controlling postoperative ocular pain and burning/stinging in a patient.
The generics of Acular Ls are possible to be released after 24 November, 2027.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8008338 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2027
(4 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8648107 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 2 months from now) | |
US8377982 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 2 months from now) | |
US9216167 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 2 months from now) | |
US8541463 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 2 months from now) | |
US8207215 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 2 months from now) | |
US8906950 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 2 months from now) | |
US8946281 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 2 months from now) | |
US8541463
(Pediatric) | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(1 year, 8 months from now) | |
US8207215
(Pediatric) | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(1 year, 8 months from now) | |
US8377982
(Pediatric) | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(1 year, 8 months from now) | |
US8008338
(Pediatric) | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2027
(4 years from now) |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 30 May, 2003
Treatment: A method of treating or preventing ocular pain and burning/stinging following corneal surgery; A method of treating ocular pain and/or enhancing ocular comfort; A method of treating or reducing ocular pain and burning/stinging; A method of controlling postoperative ocular pain and burning/stinging in a patient; A method of treating or preventing ocular pain and burning; A method of treating ocular pain; A method of treating or preventing ocular pain in a patient
Dosage: SOLUTION/DROPS;OPHTHALMIC
16
United States
2
Canada
2
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic